Es ist zu begrüßen, dass M. Dose [1] in seinem Beitrag feststellt: ¹Keinem Patienten, der von
herkömmlichen Antipsychotika nicht profitiert oder unter nicht therapierbaren Nebenwirkun …

Laakso M (University of Kuopio, Kuopio, Finland). Cardiovascular disease in type 2
diabetes: challenge for treatment and prevention (Review). J Intern Med 2001; 249: 225 …

Coronary heart disease is a major cause of morbidity in NIDDM and is likely to be related to
the abnormalities in serum lipids and lipoproteins commonly associated with it. The effects of …

Recent cases of antipsychotics-induced diabetes have focused attention on molecular
mechanisms implicated in hyperglycaemia (Luna and Feinglos, 2001). The increase in …

In addition to the common antidiabetic drugs that are widely available in many countries for
the treatment of type 1 and type 2 diabetes, a small number of drugs are approved in a …

Objective To determine coronary heart disease (CHD) incidence among dyslipidemic
subjects with non-insulin-dependent diabetes mellitus (NIDDM) and to assess the effect of …

Usual risk factors for coronary artery disease account for only 25–50% of increased
atherosclerotic risk in diabetes mellitus. Other obvious risk factors are hyperglycemia and …

Diabetes affects currently about 5% of world's populations, and its prevalence is rapidly
increasing particularly in elderly subjects. Because over 80% of all diabetic subjects have …

Overweight and obesity may develop in individuals with genetically determined low resting
energy expenditure. Drugs are among the recognised precipitating factors. The obesity …

The prevalence of type 2 diabetes (T2DM) is increasing worldwide, and macrovascular
complications account for significant T2DM morbidity and mortality. The prevention of …